KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,864 Shares of Stock

Key Points

• Insider Nicole Sweeny sold 1,864 shares of KalVista Pharmaceuticals at an average price of $13.22, reducing her stake by 6.08%.
• KalVista Pharmaceuticals reported a loss of ($3.69) earnings per share for the last quarter, significantly missing the consensus estimate of ($0.83).
• HC Wainwright raised its target price for KalVista Pharmaceuticals from $20.00 to $27.00, indicating a "buy" rating.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Nicole Sweeny sold 1,864 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $24,642.08. Following the completion of the transaction, the insider directly owned 28,771 shares of the company's stock, valued at approximately $380,352.62. This represents a 6.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Nicole Sweeny also recently made the following trade(s):

• On Monday, August 25th, Nicole Sweeny sold 1,480 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $13.42, for a total value of $19,861.60.

KalVista Pharmaceuticals Stock Performance

KALV stock traded down $0.08 during midday trading on Thursday, reaching $13.51. The stock had a trading volume of 416,522 shares, compared to its average volume of 673,960. The firm has a fifty day simple moving average of $13.47 and a two-hundred day simple moving average of $12.43. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $16.32. The stock has a market cap of $680.09 million, a PE ratio of -3.66 and a beta of 0.05.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same quarter last year, the firm posted ($1.07) earnings per share. On average, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of KalVista Pharmaceuticals by 816.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company's stock worth $91,000 after buying an additional 7,180 shares during the period. Rafferty Asset Management LLC increased its holdings in KalVista Pharmaceuticals by 78.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 46,901 shares of the specialty pharmaceutical company's stock worth $530,000 after acquiring an additional 20,632 shares in the last quarter. BNP Paribas Financial Markets raised its position in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock worth $46,000 after acquiring an additional 1,292 shares during the period. Brevan Howard Capital Management LP acquired a new position in KalVista Pharmaceuticals during the second quarter worth $151,000. Finally, Bank of America Corp DE lifted its holdings in KalVista Pharmaceuticals by 19.0% during the second quarter. Bank of America Corp DE now owns 366,966 shares of the specialty pharmaceutical company's stock valued at $4,149,000 after purchasing an additional 58,719 shares in the last quarter.

Analysts Set New Price Targets

KALV has been the topic of several research reports. JMP Securities increased their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 8th. HC Wainwright increased their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, Leerink Partners raised their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, July 7th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $26.29.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).